💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Technetium Exametazime

CHEMBL2111018 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
384.3 g/mol
LogP
—
Phase
4

Technetium exametazime (99mTc-HMPAO) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is retained in brain tissue proportional to regional cerebral blood flow, enabling SPECT perfusion imaging of the brain. It is also used to radiolabel white blood cells for scintigraphic detection of infection and inflammation. Brain SPECT with this agent is used in the evaluation of dementia, cerebrovascular disease, and psychiatric disorders.

Masse moléculaire

384,2700 g/mol

TPSA

87,10 Ų

Mécanisme d'action

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

SMILES

C[C@H](/C(=N/O)/C)[N-]CC(C)(C)C[N-][C@H](C)/C(=N/[O-])/C.O=[99Tc+3]

InChI

InChI=1S/C13H26N4O2.O.Tc/c1-9(11(3)16-18)14-7-13(5,6)8-15-10(2)12(4)17-19;;/h9-10,18-19H,7-8H2,1-6H3;;/q-2;;+3/p-1/b16-11+,17-12+;;/t9-,10-;;/m1../s1/i;;1+1

Molecular Formula

C13H25N4O3Tc

HBD / HBA

1 / 7

Liaisons Rotatives

0

Atomes Lourds

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Technetium exametazime (99mTc-HMPAO) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is retained in brain tissue proportional to regional cerebral blood flow, enabling SPECT perfusion imaging of the brain. It is also used to radiolabel white blood cells for scintigraphic detection of infection and inflammation. Brain SPECT with this agent is used in the evaluation of dementia, cerebrovascular disease, and psychiatric disorders.

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Yes, Technetium Exametazime is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2111018. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 129626367. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.